Marker Therapeutics FY2025 net loss $12.2M; cash $17M; APOLLO 66% ORR in NHL

Marker Therapeutics, Inc.

Net loss of $12.2M vs $10.7M in 2024; R&D spend $11.8M (down from $13.5M).
Cash $17M at Dec 31, 2025; expected to fund ops through Q4 2026 without new grants.
Phase 1 APOLLO data: 66% objective response rate in relapsed NHL, 50% complete responses.
MT-601 pancreatic cancer program to initiate in Q2 2026; Nature Medicine publication Jan 2026.
New board member Kathryn Penkus Corzo appointed Nov 2025; Cellipont manufacturing collaboration.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-26-031309
form_type: 8-K
ticker: MRKR
cik: 0001094038
company_name: Marker Therapeutics, Inc.
filed_at: 2026-03-19T23:59:59+00:00
discovered_at: 2026-05-14T18:02:34.530119+00:00
generated_at: 2026-05-15T09:34:26.770302+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-26-031309
json_url: https://secwatch.observer/filing/0001104659-26-031309.json
markdown_url: https://secwatch.observer/filing/0001104659-26-031309.md
text_url: https://secwatch.observer/filing/0001104659-26-031309.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465926031309/0001104659-26-031309-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465926031309/tm268941d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-26-031309

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.